Although large, randomized, controlled trials are still needed to clarify the effects of β2AR agonists on the risk of PD [127], it is worth highlighting that H3K27 acetylation of SNCA can be regulated in a level-dependent manner by both β2AR agonists (down) and antagonists (up) [94]. This evidence concerns the gene ADRB2 and Parkinson disease.